Ventoxen 100mg (Venetoclax)

Ventoxen — Targeted Cancer Therapy for CLL, SLL, and AML

Ventoxen is an effective and affordable generic alternative to VENCLEXTA, designed to provide targeted therapy for chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and acute myeloid leukemia (AML). It delivers reliable results for patients and trusted value for healthcare partners.

Conditions Treated:

Ventoxen supports treatment for several blood cancers by helping stop cancer cell growth and improving clinical outcomes for eligible patients.

Category: Blood cancer Brand: Everest Pharmaceuticals Ltd.

Scan to Order

Order Now +8801575308158

Description
Reviews (0)

Ventoxen — Targeted Cancer Therapy for CLL, SLL, and AML

SLL (small lymphocytic lymphoma) is closely related to CLL. However, SLL cancer cells are mostly found in the lymph nodes rather than in the blood and bone marrow. Both are types of non-Hodgkin lymphoma and involve immature white blood cells. Usually affects people 65 and older but can occur as early as 30.

Indications:

Ventoxen in combination with Rituximab is indicated for the treatment of adult patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy.

Ventoxen monotherapy is indicated for the treatment of CLL:

In the presence of 17p deletion or TP53 mutation in adult patients who are unsuitable for or have failed a B-cell receptor pathway inhibitor, or
In the absence of 17p deletion or TP53 mutation in adult patients who have failed both chemoimmunotherapy and a B-cell receptor pathway inhibitor.

Pharmacology:

Venetoclax is a selective and orally bioavailable small-molecule inhibitor of BCL-2, an antiapoptotic protein. Overexpression of BCL-2 has been demonstrated in CLL cells where it mediates tumor cell survival and has been associated with resistance to chemotherapeutics. Venetoclax helps restore the process of apoptosis by binding directly to the BCL-2 protein, displacing pro-apoptotic proteins like BIM, triggering mitochondrial outer membrane permeabilization and the activation of caspases. In nonclinical studies, venetoclax has demonstrated cytotoxic activity in tumor cells that overexpress BCL-2.

Dosage:

The starting dose is 20 mg of Venetoclax once daily for 7 days. The dose must be gradually increased over a period of 5 weeks up to the daily dose of 400 mg. The 5-week dose-titration schedule is designed to gradually reduce tumour burden (debulk) and decrease the risk of tumor lysis syndrome.

Post-titration dose for Venetoclax in combination with Rituximab:

The recommended dose of Venetoclax in combination with Rituximab is 400 mg once daily. Rituximab should be administered after the patient has completed the dose-titration schedule and has received the recommended daily dose of 400 mg Venetoclax for 7 days. Venetoclax should be taken for 24 months from Cycle 1 Day 1 of Rituximab.

Post-titration dose for Venetoclax monotherapy:

The recommended dose of Venetoclax is 400 mg once daily. Treatment should be continued until disease progression or no longer tolerated by the patient.

Side Effects:

The most commonly occurring side effects (>20%) of any grade in patients receiving Ventoxen in the combination study with Rituximab were neutropenia, diarrhoea, and upper respiratory tract infection. In the monotherapy studies, the most common side effects were neutropenia/neutrophil count decreased, diarrhoea, nausea, anaemia, fatigue, and upper respiratory tract infection. The most frequently reported serious side effects (>2%) in patients receiving Ventoxen in combination with Rituximab were pneumonia, febrile neutropenia, and TLS. In the monotherapy studies, the most frequently reported serious side effects (>2%) were pneumonia and febrile neutropenia.

Overdose Effect:

There is no specific antidote for Ventoxen. Patients who experience overdose should be closely monitored and appropriate supportive treatment provided. During dose-titration phase, treatment should be interrupted and patients should be monitored carefully for signs and symptoms of TLS (fever, chills, nausea, vomiting, confusion, shortness of breath, seizures, irregular heartbeat, dark or cloudy urine, unusual tiredness, muscle or joint pain, abdominal pain and distension) along with other toxicities.

Therapeutic Class:

Cytotoxic Chemotherapy

Storage Condition:

Store below 30°C. Keep Ventoxen out of the sight and reach of children. Protect from moisture and light…

Reviews

There are no reviews yet.

Be the first to review “Ventoxen 100mg (Venetoclax)”

Ventoxen 100mg (Venetoclax)

Ventoxen — Targeted Cancer Therapy for CLL, SLL, and AML